In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Inc.

www.pfizer.com

Latest From Pfizer Inc.

The Return of The Pazdur Moment

US FDA’s top cancer drug reviewer has been uncharacteristically quiet during recent advisory committee meetings. That just changed, and the result may not have been great for the sponsor (Pfizer), but it is a reminder of the value that Pazdur’s institutional knowledge and outspokenness bring to all of FDA.

Advisory Committees Cancer

Keen Kevzara Pricing Will Be Sanofi’s Best Hope After Speedy NICE Nod

A three-month turnaround from approval in Europe for Sanofi’s rheumatoid arthritis drug to recommendation in England is pretty quick. The firm will need to maintain keen pricing in a competitive field.

Immune Disorders Reimbursement

Pipeline Watch: Phase III Progress With Lefamulin, Dupilumab, Patisiran

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Approvals Pipeline Watch

VELOCITY Failure For Versartis's Lead Drug Sends Shares Into Tailspin

Versartis's long-acting growth hormone product missed Phase III non-inferiority endpoint, wiping more than 83% of the company's value.

Clinical Trials Companies
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register